Genzyme GMP failures now irk patients as well as regulators, lawyers and shareholders; Baxter expands for cytotoxics in Germany;

> Some Genzyme patients have told the New York Times that they feel "betrayed" by the drug company they once viewed as savior, wondering why Genzyme had insufficient reserves of drugs vital to them, and how it could have responded so poorly in fixing its manufacturing problems. Article

> Baxter is expanding its cytotoxic contract manufacturing facility in Halle, Germany, for the third time. Article

> Russian homeopathic drug manufacturer of Materia Medica has signed with contract manufacturer Angel Biotechnology for process development and GMP manufacture of specific antibodies. Article

> DHL reports "a record number of movements" of finished pharmaceuticals, vaccines, medical equipment and devices, and clinical trial supplies in Asia, yielding 7 percent growth in its Life Sciences & Healthcare business. Item

> Corning is displaying its newest glass reactor product, a low-flow glass reactor that the company says aids in the transition to higher-volume, continuous-flow chemical processing, at Interphex. Release

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.